HOFFMANN-LA ROCHE

PADOVA

This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients. This is a 5-year extension study to PASEDENA.

Status: ACTIVE, NOT RECRUITING